Literature DB >> 24566617

Immunomodulatory glycan lacto-N-fucopentaose III requires clathrin-mediated endocytosis to induce alternative activation of antigen-presenting cells.

Leena Srivastava1, Smanla Tundup, Beak-San Choi, Thomas Norberg, Donald Harn.   

Abstract

The mechanism of alternative activation of antigen-presenting cells (APCs) is largely unknown. Lacto-N-fucopentaose III (LNFPIII) is a biologically conserved pentasaccharide that contains the Lewis(x) trisaccharide. LNFPIII conjugates and schistosome egg antigens, which contain the Lewis(x) trisaccharide, drive alternative activation of APCs and induce anti-inflammatory responses in vivo, preventing inflammation-based diseases, including psoriasis, transplant organ rejection, and metabolic disease. In this study, we show that LNFPIII conjugates and schistosome egg antigens interact with APCs via a receptor-mediated process, requiring internalization of these molecules through a clathrin/dynamin-dependent but caveolus-independent endocytic pathway. Using inhibitors/small interfering RNA (siRNA) against dynamin and clathrin, we show for the first time that endocytosis of Lewis(x)-containing glycans is required to drive alternative maturation of antigen-presenting cells and Th2 immune responses. We identified mouse SIGNR-1 as a cell surface receptor for LNFPIII conjugates. Elimination of SIGNR-1 showed no effect on uptake of LNFPIII conjugates, suggesting that other receptors bind to and facilitate uptake of LNFPIII conjugates. We demonstrate that disruption of actin filaments partially prevented the entry of LNFPIII conjugates into APCs and that LNFPIII colocalizes with both early and late endosomal markers and follows the classical endosomal pathway leading to lysosome maturation. The results of this study show that the ability of LNFPIII to induce alternative activation utilizes a receptor-mediated process that requires a dynamin-dependent endocytosis. Thus, key steps have been defined in the previously unknown mechanism of alternative activation that ultimately leads to induction of anti-inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24566617      PMCID: PMC3993454          DOI: 10.1128/IAI.01293-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  67 in total

1.  Structure of a C-type carbohydrate recognition domain from the macrophage mannose receptor.

Authors:  H Feinberg; S Park-Snyder; A R Kolatkar; C T Heise; M E Taylor; W I Weis
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

2.  Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblasts: implications for vector-dependent plasmid transfection.

Authors:  Pierre Pellegrin; Anne Fernandez; Ned J C Lamb; René Bennes
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

Review 3.  Alternative activation of macrophages.

Authors:  Siamon Gordon
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

4.  Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response.

Authors:  M Okano; A R Satoskar; K Nishizaki; D A Harn
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

5.  The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x.

Authors:  Irma van Die; Sandra J van Vliet; A Kwame Nyame; Richard D Cummings; Christine M C Bank; Ben Appelmelk; Teunis B H Geijtenbeek; Yvette van Kooyk
Journal:  Glycobiology       Date:  2003-02-20       Impact factor: 4.313

6.  A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(+) macrophages that suppress naive CD4(+) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism.

Authors:  O Atochina; T Daly-Engel; D Piskorska; E McGuire; D A Harn
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

7.  Both free-living and parasitic nematodes induce a characteristic Th2 response that is dependent on the presence of intact glycans.

Authors:  Salah Tawill; Laetitia Le Goff; Fahimeda Ali; Mark Blaxter; Judith E Allen
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism.

Authors:  Paul G Thomas; Michele R Carter; Olga Atochina; Akram A Da'Dara; Danuta Piskorska; Edward McGuire; Donald A Harn
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

Review 9.  Glycoconjugates from parasitic helminths: structure diversity and immunobiological implications.

Authors:  K H Khoo; A Dell
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

10.  Toll-like receptors induce a phagocytic gene program through p38.

Authors:  Sean E Doyle; Ryan M O'Connell; Gustavo A Miranda; Sagar A Vaidya; Edward K Chow; Philip T Liu; Shinobu Suzuki; Nobutaka Suzuki; Robert L Modlin; Wen-Chen Yeh; Timothy F Lane; Genhong Cheng
Journal:  J Exp Med       Date:  2003-12-29       Impact factor: 14.307

View more
  14 in total

1.  Bacterial Glycoengineering as a Biosynthetic Route to Customized Glycomolecules.

Authors:  Laura E Yates; Dominic C Mills; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 2.  Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes?

Authors:  Nedim Durmus; Sung-Hyun Park; Joan Reibman; Gabriele Grunig
Journal:  Curr Opin Rheumatol       Date:  2016-11       Impact factor: 5.006

3.  Neurochemical and neuroinflammatory perturbations in two Gulf War Illness models: Modulation by the immunotherapeutic LNFPIII.

Authors:  J M Carpenter; H E Gordon; H D Ludwig; J J Wagner; D A Harn; T Norberg; N M Filipov
Journal:  Neurotoxicology       Date:  2019-12-19       Impact factor: 4.294

4.  Fasciola hepatica Surface Coat Glycoproteins Contain Mannosylated and Phosphorylated N-glycans and Exhibit Immune Modulatory Properties Independent of the Mannose Receptor.

Authors:  Alessandra Ravidà; Allison M Aldridge; Nicole N Driessen; Ferry A H Heus; Cornelis H Hokke; Sandra M O'Neill
Journal:  PLoS Negl Trop Dis       Date:  2016-04-22

5.  Schistosome egg antigens, including the glycoprotein IPSE/alpha-1, trigger the development of regulatory B cells.

Authors:  Simone Haeberlein; Katja Obieglo; Arifa Ozir-Fazalalikhan; Mathilde A M Chayé; Henrike Veninga; Luciën E P M van der Vlugt; Astrid Voskamp; Louis Boon; Joke M M den Haan; Lotte B Westerhof; Ruud H P Wilbers; Arjen Schots; Gabriele Schramm; Cornelis H Hokke; Hermelijn H Smits
Journal:  PLoS Pathog       Date:  2017-07-28       Impact factor: 6.823

Review 6.  Parasite-Derived Proteins for the Treatment of Allergies and Autoimmune Diseases.

Authors:  Zhenyu Wu; Lifu Wang; Yanlai Tang; Xi Sun
Journal:  Front Microbiol       Date:  2017-11-07       Impact factor: 5.640

Review 7.  Myeloid C-type lectin receptors in skin/mucoepithelial diseases and tumors.

Authors:  Ce Tang; Yulia Makusheva; Haiyang Sun; Wei Han; Yoichiro Iwakura
Journal:  J Leukoc Biol       Date:  2019-04-09       Impact factor: 4.962

8.  Sweet secrets of a therapeutic worm: mass-spectrometric N-glycomic analysis of Trichuris suis.

Authors:  Iain B H Wilson; Katharina Paschinger
Journal:  Anal Bioanal Chem       Date:  2015-12-09       Impact factor: 4.142

9.  A Comparison of Two Structurally Related Human Milk Oligosaccharide Conjugates in a Model of Diet-Induced Obesity.

Authors:  Jessica Ramadhin; Vanessa Silva-Moraes; Tamas Nagy; Thomas Norberg; Donald Harn
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

10.  A Neoglycoconjugate Containing the Human Milk Sugar LNFPIII Drives Anti-Inflammatory Activation of Antigen Presenting Cells in a CD14 Dependent Pathway.

Authors:  Smanla Tundup; Leena Srivastava; Thomas Norberg; Wendy Watford; Donald Harn
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.